Youn-Hyun Kim1,2, Petra Nijst1, Kathryn Kiefer1, W H Wilson Tang3. 1. , 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA. 2. Cardiovascular Division, Department of Internal Medicine, Korea University Ansan Hospital, Ansan-si, Republic of Korea. 3. , 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA. tangw@ccf.org.
Abstract
INTRODUCTION: The endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents. RECENT FINDINGS: Among the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may indicate the degradation of eGC. In patients with ischemic heart disease or heart failure, elevation of serum sdc1 has been associated with worsening cardiac and renal function; however, the causal relationship between degradation of eGC and clinical outcomes is unclear. Herein, we review the previous literature on eGC in cardiovascular and noncardiovascular diseases and their clinical implications.
INTRODUCTION: The endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents. RECENT FINDINGS: Among the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may indicate the degradation of eGC. In patients with ischemic heart disease or heart failure, elevation of serum sdc1 has been associated with worsening cardiac and renal function; however, the causal relationship between degradation of eGC and clinical outcomes is unclear. Herein, we review the previous literature on eGC in cardiovascular and noncardiovascular diseases and their clinical implications.
Authors: Matthias Jacob; Thomas Saller; Daniel Chappell; Markus Rehm; Ulrich Welsch; Bernhard F Becker Journal: Basic Res Cardiol Date: 2013-04-06 Impact factor: 17.165
Authors: Max Nieuwdorp; Hans L Mooij; Jojanneke Kroon; Bektas Atasever; Jos A E Spaan; Can Ince; Frits Holleman; Michaela Diamant; Robert J Heine; Joost B L Hoekstra; John J P Kastelein; Erik S G Stroes; Hans Vink Journal: Diabetes Date: 2006-04 Impact factor: 9.461
Authors: Bernhard F Becker; Matthias Jacob; Stephanie Leipert; Andrew H J Salmon; Daniel Chappell Journal: Br J Clin Pharmacol Date: 2015-05-22 Impact factor: 4.335
Authors: Daniel Chappell; Nina Dörfler; Matthias Jacob; Markus Rehm; Ulrich Welsch; Peter Conzen; Bernhard F Becker Journal: Shock Date: 2010-08 Impact factor: 3.454
Authors: Mark W M Schellings; Davy Vanhoutte; Geert C van Almen; Melissa Swinnen; Joost J G Leenders; Nard Kubben; Rick E W van Leeuwen; Leo Hofstra; Stephane Heymans; Yigal M Pinto Journal: Hypertension Date: 2010-01-04 Impact factor: 10.190
Authors: Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Sathyen A Prabhu; Matthew Gliksman; Betty Tai; Ahmet Hatipoglu; Andre Goy; K Stephen Suh Journal: Oncotarget Date: 2015-10-06
Authors: Timo Vögtle; Sumana Sharma; Jun Mori; Zoltan Nagy; Daniela Semeniak; Cyril Scandola; Mitchell J Geer; Christopher W Smith; Jordan Lane; Scott Pollack; Riitta Lassila; Annukka Jouppila; Alastair J Barr; Derek J Ogg; Tina D Howard; Helen J McMiken; Juli Warwicker; Catherine Geh; Rachel Rowlinson; W Mark Abbott; Anita Eckly; Harald Schulze; Gavin J Wright; Alexandra Mazharian; Klaus Fütterer; Sundaresan Rajesh; Michael R Douglas; Yotis A Senis Journal: Elife Date: 2019-08-22 Impact factor: 8.140
Authors: Edmund Y M Chung; Katie Trinh; Jennifer Li; Sebastian Hayden Hahn; Zoltan H Endre; Natasha M Rogers; Stephen I Alexander Journal: Front Cardiovasc Med Date: 2022-05-20
Authors: Olga G Grushko; Steven Cho; Ashley M Tate; Robert S Rosenson; David J Pinsky; Jacob M Haus; Scott L Hummel; Sascha N Goonewardena Journal: Cardiovasc Drugs Ther Date: 2022-10-19 Impact factor: 3.947
Authors: Marina M Ziganshina; Ekaterina L Yarotskaya; Nicolai V Bovin; Stanislav V Pavlovich; Gennady T Sukhikh Journal: Int J Mol Sci Date: 2020-04-26 Impact factor: 5.923